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1. Introduction
  Liver cancer is the most common malignant tumors, 
which including hepatocellular carcinoma and metastatic 
liver cancer. China is a high prevalence area of liver 
cancer with the high incidence rate and mortality. Primary 
hepatocellular carcinoma (HCC) is one of the most common 
clinical malignant tumor, it is the second largest cause of 
cancer related death. The number of new cases in china 
every year is occupy 55% of the world, which has greatly 
threatened human health[1-3]. Conventional treatment 
in clinical are surgery, chemotherapy and radiotherapy. 
Surgery is the preferred treatment for liver cancer, which 
with low resection rate and poor prognosis, only small 
portion of patients with satisfactory results. There is 
cirrhosis with most of the liver cancer patients, and also 
associated with hypersplenism and peripheral hypocytosis. 
Liver cancer patients’ also unbearable to systemic 
chemotherapy; Radiation therapy is usually only for liver 
function is still good and without complication (such as 
cirrhosis, ascites, jaundices) and without distant metastasis, 
so the range for radiation therapy is relatively narrow. Other 
optional treatments include immunotherapy and traditional 
Chinese medicine, but these treatments have poor effect, so 
the clinical application is relatively limited[4-6].
  The earliest occurrence of liver cancer metastasis is in 
the liver and easily invasive the hepatic portal vein and 
its branches then form a tumor thrombu. Tumor thrombus 
exfoliated and caused multiple metastases in the liver. 
The extrahepatic metastasis include blood metastasis 
(lung metastasis has the highest metastaic rate), lymph 
node metastasis and implantation metastasis[7,8]. There 
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are two main forms of mammalian target of rapamycin 
(mTOR), which can participate in a series of intracellular 
physiological and pathological processes: mTOR-Raptor 
complex and the mTOR-Rictor complex. mToR-Raptor 
complex was found earlier than the mTOR-Rietor complex, 
which can regulate protein synthesis in cells and affect the 
growth and proliferation of cells[9,10]. Signal transduction and 
activator of transcription 3 (STAT3) is a bifunctional protein 
that mainly exists in cytoplasm. It can couple to tyrosine 
phosphorylation signal channel and play an important role, 
such as regulate the expression of a variety of proteins 
related to the cell proliferation and apoptosis. Excessive 
activation of STAT3 in cells can promote cell proliferation 
and inhibit apoptosis, it can also promote angiogenesis and 
involved in the regulation of tumor cells immune escape. 
Excessive activation of STAT3 is considered to be one of 
the important mechanisms of tumorigenesis, the abnormal 
activation of STAT3 also showed in multiple hepatoma cell 
strains[11-14].
  In this study, we blocked the expression of mTOR and 
observed its effect on regulating the STAT3, and further 
observed the effect on liver cancer cell invasion and 
metastasis, try to find new direction for the treatment of liver 
cancer and the inhibition of liver cancer metastasis.
2. Materials and methods
2.1. Main materials
  The HepG2 and L02 cells were purchased from Shanghai 
Cell Bank. mTOR antibody, STAT3 antibody, 毬-actin 
antibody were purchased from ABcam Company, 
correpondding anti antibody were purchased from Beijing 
Zhongshan Jinqiao Company. RNA extraction Trizol, 
transfection reagent Lipo-fectamine 2000 were purchased 
from Invitrogen Corporation. RT-PCR kit was purchased 
from Fermentas company.
2.2. Experimental methods
2.2.1. Cell transfection and grouping
  Human hepatoma cell line HepG2 was cultured in RPMI1640 
medium containing 10% fetal bovine serum, then was placed 
in 5% CO2 37 曟 constant temperature incubator. According 
to 434-452 sites of mTOR gene, the oligonucleotide template 
and the nonsense templates was designed and synthesized 
(negative control nonsense templates had no homology 
with any coding sequence) (Table 1), oligo-1 and oligo-2, 
oligo-3 and oligo-4 of each template were complement to 
DNA duplexes. Two double-stranded DNA were transcribed 
to produce the siRNA sense strand and antisense strand 
respectively, after double-stranded siRNA was obtained, 
20 bp DNA Ladder Marker was used as a reference and 
was identified by agarose gel electrophoresis. During 
transfection, the siRNA/liposome complex was placed at 
room temperature for 20 min, then the cells were added to 
be transfected, then they were mixed and observed after 24 
h culture. Groups were as follows (n=3): HepG2 cells without 
any treatment as control group, transfected negative control 
sequence HepG2 as negative control group, transfected 
mTOR-siRNA HepG2 as experimental group. After 48 h
of transfection, cells were collected by trypsin digestion.
  Cells in each group were collected after 48 h transfection. 
Conventional method Trizol reagent was used for 
total RNA extraction and reverse transcription was 
performed. mTOR gene primer sequence upstream: 
5’CGCTGTCATCCCTTTATCG3’ ;  primer downstream 
sequence: 5’ATGCTCAAACACCTCCACC3’. Internal 
re fe rence  GAPDH pr imer  ups t ream sequences : 
5’GCACCGTCAAGGCTGAGAA3’; primer downstream 
sequence: 5 ’AGGTCCACCACTGACACGTTF3 ’ .  PCR 
conditions were set as follows: 95 曟 10 min, 95 曟 15 s, 53 曟
30 s, 72 曟 30 s, 40 cycles. Parallel experiments were 
repeated three times.
2.2.2. Western blotting
  Cells were collected and protein was extrected 
Table 1
Targeting mTOR siRNA transcriptional template sequences.
Sequence name Sequence
siRNA oligo-1 5’-AAGATAGTTGGCAAATCTGCCTATAGTGAGTCGTATTAGGATCC-3’
oligo-2 5’-GGATCCTAATACGACTCACTATAGGCAGATTTGCCAACTATC-3’
oligo-3 5’-AAGGCAGATTTGCCAACTATCTATAGTGAGTCGTATTAGGATCC-3’
oligo-4 5’-GGATCCTAATACGACTCACTATAGATAGTTGGCAAATCTGCC-3’
siRNA-control oligo-1 5’-AAGGCCATAATCAAGAAATACTATAGTGAGTCGTATTAGGATCC-3’
oligo-2 5’-GGATCCTAATACGACTCACTATAGTATTTCTTGATTATGGCCTT-3’
oligo-3 5’-AAGTATTTCTTGATTATGGCCTATAGTGAGTCGTATTAGGATCC-3’
oligo-4 5’-GGATCCTAATACGACTCACTATAGGCCATAATCAAGAAATACTT-3’
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byconventional method. After protein quantification, SDS-
PAGE separation and PVDF transfer, Western blot method 
was used to detect mTOR and STAT3 expressions.
2.2.3. HepG2 cells basement membrane invasive ability 
detection
  Transwell upper chamber surface was coated by Matrigel 
5 毺g, and was air dried at 4 曟, basement membrane was 
hydrated, and 500 毺L culture medium (containing FBS 
or chemokines) was added in Transwell lower chamber. 
Transfected cells and non-transfected cells were collected 
after 48 h, cell density was adjusted to 1伊106/mL. 200 
毺L was then added to each Transwell chamber. The 
Transwell plate was cultured in 5% CO2 37 曟, after 24 h 
the chamber was removed and the cells were washed with 
PBS. Noninvasive cells were wiped off with a cotton on 
matrix gelatin and the surface of upper chamber, fixed with 
methanol, stained with crystal violet and washed with PBS. 
Five fields of vision were selected randomly from each slice 
for 200 times microscopic observation and the number of 
invasion cells which through basement membrane were 
counted. Mean value was regarded as the invasion and 
metastasis number. This test was repeated for three times.
2.2.4. Scratch adhesion test
  After grouping, cells in 24-well plate were seeded. When 
the cells grew to 90% confluence, three straight lines 
were drawn for the cells in each well with 10 毺L pipette 
tip. They were washed with PBS for three times, then 
cultured in the medium for 24 h. Five fields of vision were 
selected randomly from cells in each well for microscopic 
observation. There were 3 parallel holes at every group and 
each well was repeated twice.
2.3. Statistical analysis
  The measurement data were expressed as mean依SD values 
and the difference between each group were analyzed by 
SPSS/Win13.0 software (SPSS, Chicago, IL). One-Way ANOVA 
was applied in the comparison between groups, P<0.05 has 
statistical significance.
3. Results
3.1. Hepatoma cells and normal liver cells mTOR and STAT3 
expression
  The results showed that the expression of HepG2 cells was 
higher than L02 cells (P<0.05) (Figure 1).
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Figure 1. Hepatoma cells and normal liver cells mTOR and STAT3 
expression.
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Figure 2. The mTOR and STAT3 expression of hepatoma cells and 
normal liver cells.
3.2. Transfection cells mTOR expression
   This showed successful transfection and siRNA 
interference blocked the expression of mTOR. Compared 
with the control group, the Western blot detection showed 
that the STAT3 protein expression was also significantly 
decreased (P<0.05) after blocking the expression of mTOR.
3.3. mTOR blocking on HepG2 invasion and metastatic 
ability
  After transfection blocking of the mTOR expression, 
use Transwell assay to detect the change of HepG 2 cell 
basement membrane invasion ability. As shown in Figure 3, 
the number of passed membrane cells in the blank group, the 
control group and the transfection group were 289依17, 291依
16, 67依12. Compared with the blank group and the control 
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group, the number of passed membrane cells decreased 
significantly (P<0.05).Compared the blank group with the 
control group, there is no statistically significant (P>0.05).
Blank group                            Control group                     Transfection group
 
Figure 3. Transwell cell invasion ability detection (200伊).
  After transfection of siRNA blocked the expression of 
mTOR, scratch adhesion test showed the scratch width of the 
blank group, control group and transfection group were 1.35
依0.29, 1.26依0.38, 0.63依0.42 mm respectively, Compared with 
the blank group and the control group, the migration of the 
cells in MTOR siRNA transfection group was significantly 
decreased, scratch healing speed was significantly 
decreased (P＜0.05), while compare the scratch width of the 
blank group with the control group, the differences between 
two groups have no statistically significant (P> 0.05).
4. Discussion
  With the gradual deepening study of the mTOR signals 
pathway recently, MTOR signaling pathway conduction was 
found closely related with a variety of tumor occurrence 
and development, especially in the process of cell growth 
and proliferation of mTOR signaling pathway. However, the 
mechanism of mTOR gene on liver cancer cells invasion 
and metastasis is still not clear. In this study, we design 
and synthesize siRNA sequences which aiming at mTOR 
gene, and use it to transfected human hepatoma cell line 
HepG2, observed its effect on liver cancer cell invasion 
and metastasis. After 48 h of siRNA transfection, detected 
the expression of mTOR at the gene level and protein level 
respectively. The results showed that: mTOR with high 
expression in the non-transfected mTOR-siRNA blank 
control group, while after the mTOR siRNA transfection, 
successfully blocked its expression at the mRNA level 
and protein level. This indicates that the design of siRNA 
sequences successfully blocked the expression of mTOR. 
The mTOR siRNAture we designed can be used as tools 
for the further study of liver cancer occurrence and 
development, invasion and metastasis[15-17].
  In the basic characteristics of malignant tumors, invasion 
and metastasis are the important aspect, which are also 
the main factors lead to cancer recurrence and mortality.
During the treatment of liver cancer, the key factors include 
the control of tumor invasion and metastasis[18-21]. Recent 
studies showed that STAT3 signaling pathway plays an 
important role in the incidence and the development 
of cancer, especially in the promotion of tumor cell 
proliferation, inhibition of tumor cell apoptosis, promote 
tumor cell invasion and metastasis and immune escape, 
STAT3 signaling pathway is particularly important[17,22-
25]. In this study, we further demonstrated the role of mTOR 
in the regulation of STAT3. After blocking mTOR, STAT3 
expression was significantly reduced, which provides more 
powerful evidence that mTOR as therapeutic target of liver 
cancer metastasis.
  In this study, we used Transwell invasion assay in vitro 
to detect cell invasion. The numbers of passed membrane 
cells were used as characterization to evaluate the changes 
of HepG2 cells invasive ability before and after siRNA 
transfection. The results showed that the mTOR siRNA 
transfection cells can successfully block the expression 
of mTOR. Compared cells invasive ability of transfected 
cells with non-transfected cells, the cell invasion was 
significantly decreased after siRNA blocked mTOR 
expression. This indicates mTOR is an important regulatory 
factor in the process of invasion and metastasis of HCC, 
which plays an important regulatory role. This effect may 
because it can regulate STAT3.
  In conclusion, this study further confirmed mTOR and 
STAT3 with high expression in liver cancer cells. After 
blocking mTOR expression, the expression of STAT3 also 
reduced, further validates mTOR can regulate STAT3. And 
the experimental results showed that mTOR-STAT signaling 
down-regulation significantly inhibited the invasion and 
metastasis of liver cancer cells, which provide potential new 
ideas for the liver cancer anti-metastatic treatment. Follow-
up studies also need to study the STAT3 further downstream 
signal transduction after blocking mTOR, so that can have 
deeper researches in the role of mTOR/STAT3 signaling 
pathways in liver metastasis.
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